Lifeboat Foundation

COSMOS: POSSIBLE WORLDS is helmed by Carl Sagan’s collaborator Ann Druyan, who boldly carries the torch forward with the 3rd season of the most beloved science show on the planet. Series premieres 3/9, at 8/7c, on Nat Geo; hosted by Neil deGrasse Tyson.
➡ Subscribe: http://bit.ly/NatGeoSubscribe

About National Geographic:
National Geographic is the world’s premium destination for science, exploration, and adventure. Through their world-class scientists, photographers, journalists, and filmmakers, Nat Geo gets you closer to the stories that matter and past the edge of what’s possible.

Continue reading “COSMOS SEASON 3 TRAILER | National Geographic” »

To date, teaching a robot to perform a task has usually involved either direct coding, trial-and-error tests or handholding the machine. Soon, though, you might just have to perform that task like you would any other day. MIT scientists have developed a system, Planning with Uncertain Specifications (PUnS), that helps bots learn complicated tasks when they’d otherwise stumble, such as setting the dinner table. Instead of the usual method where the robot receives rewards for performing the right actions, PUnS has the bot hold “beliefs” over a variety of specifications and use a language (linear temporal logic) that lets it reason about what it has to do right now and in the future.

YouTuber Tom Scott has a new video where he stands in front of a laser and stops it in midair. “Can this burn me?” he asks the guest expert at one point. (The answer is just, “Yeah.”)

Fossils of rangeomorphs, which dominated the oceans more than a half-billion years ago, show the thin threads that connected them.

I’m nothing… You are nothing… We all nothing…

New evidence reignites a longstanding debate about how the sea reconnected with the ocean.

Takeda said it has begun development of TAK-888, an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) designed to treat high-risk individuals with COVID-19.

Takeda’s H-IGs are plasma derived-therapies that have previously shown effectiveness in treating of severe acute viral respiratory infections. Such therapies are designed to concentrate pathogen-specific antibodies from plasma collected from recovered patients or vaccinated donors in the future. By transferring the antibodies to a new patient, Takeda reasons, a person’s immune system can better respond to the infection and increase their chance of recovery.

Two big-name biopharmas—Takeda Pharmaceutical and Alnylam Pharmaceuticals—have separately entered the scramble to develop new treatments for SARS-CoV-2 infection, the virus identified as the cause of the global COVID-19 outbreak. [NIH].

Continue reading “Coronavirus: Takeda Pursues Plasma-Derived Treatment; Alnylam and Vir Eye siRNA Therapy” »

Another year, another wacky Goodyear tire concept.

https://www.youtube.com/watch?v=sdLyUZnGKGY&feature=youtu.be